BCL-2 Expression in Node-Negative Breast Cancer
Author Information
Author(s): H-J van Slooten, PC Clahsen, JH van Dierendonck, Ch Duva, C Pallud, A-M Mandard, A Delobelle-Deroide, CJH van de Velde, MJ van de Vijver
Primary Institution: Leiden University Hospital
Hypothesis
Does BCL-2 expression predict response to chemotherapy in node-negative breast cancer patients?
Conclusion
BCL-2 expression is associated with favorable prognosis but does not predict response to chemotherapy.
Supporting Evidence
- High BCL-2 expression correlates with estrogen and progesterone receptor positivity.
- Patients with high BCL-2 expression had better disease-free and overall survival.
- BCL-2 expression does not predict response to chemotherapy in this patient group.
Takeaway
This study looked at how a protein called BCL-2 affects breast cancer treatment. It found that while high levels of BCL-2 are linked to better outcomes, they don't help doctors know if chemotherapy will work.
Methodology
The study used immunohistochemistry to assess BCL-2 expression in tumor samples from premenopausal, lymph node-negative breast cancer patients who were randomized to receive chemotherapy or not.
Limitations
BCL-2 was not found to be an independent prognostic factor in multivariate analysis.
Participant Demographics
Premenopausal women with node-negative early breast cancer.
Statistical Information
P-Value
P=0.004 for disease-free survival, P=0.009 for overall survival
Confidence Interval
95% CI 0.35-1.06
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website